Approximately 90% of PTLD cases are EBV positive based on tumor analysis. 1 EBV immortalizes B lymphocytes, a feature that is thought to promote the development of PTLD, especially in the absence of T cell regulation consequent to immunosuppressive therapies. 3 Pediatric patients are often EBV-naïve at transplantation, which places them at increased risk for PTLD, especially if they receive an EBV-seropositive donor organ. 3 The level of EBV DNA in WB or plasma has been identified as a possible predictor for PTLD. 3 However, consensus around the absolute VL threshold associated with PTLD does not exist, and VL monitoring of blood alone has not been sufficient to predict PTLD. 3 It is hypothesized that more accurate and consistent monitoring strategies may help providers stratify individual patient PTLD risk to promote early intervention to diminish risk and decrease PTLD.
Michelson et al. analyzed a retrospective cohort of EBV Donor+/
Recipient− (D+/R−) lung and heart-lung transplant patients at PTLD diagnosis and found that elevated EBV levels in BAL fluid correlated with PTLD more closely than levels in peripheral blood. 4 However, the study was limited by sample size, retrospective design, and limited pre-PTLD samples. Limited samples hindered the ability to assess predictive capability; therefore, prospective, multicenter studies were suggested to verify the results. 4 This study seeks to evaluate and compare the utility of measuring EBV in BAL fluid and WB to predict PTLD in a prospective cohort of pediatric lung transplant recipients.
| METHODS
A multicenter, prospective, observational cohort study of the 61 pedi- Because the assay standard curve did not allow quantitation of VL <2000 copies/mL, a category into which many samples from the present study fell, CT was used for statistical comparisons between all groups with a CT of approximately >35 consistent with VL<2000 copies/mL.
| Statistical methods
Data collected from the clinical sites and core laboratories were sup- 
| RESULTS
This prospective cohort consisted of 61 pediatric lung (n=56) or heart-lung transplant (n=5) recipients. Thirty-six (59%) were female.
The mean age at transplantation was 12.2 years (range 0.7-19.1). was female, and all were white. The average age at transplantation was 14.9 years (range 11.9-17.6) ( 
| DISCUSSION
PTLD is a life-threatening complication of pediatric lung and heartlung transplantation for which a biomarker for disease onset and progression is lacking; to date, monitoring strategies inadequately predicts the development of PTLD in this patient population. This study sought to evaluate serial monitoring of EBV DNA levels in BAL fluid of pediatric lung or heart-lung transplant patients as a predictor of PTLD and to investigate whether measuring EBV load in BAL fluid provides additional value to monitoring in blood. T A B L E 4 EBV PCR CT for D+/R− grouped by BAL/WB (values in cycle number). Mean and range for each specimen type are based on subject-means (due to uneven numbers of observations among subjects). Differences between PTLD and non-PTLD groups were estimated based on linear random (subject) effects model (using actual, observation-level data) negative EBV DNA testing underscores the previously reports of poor positive predictive value and highly reliable negative predictive value of EBV DNA testing. 3 The number of PTLD patients (n=4) and the diversity of PTLD sites including two with disseminated disease in the cohort limit the generalizability of the present study. Additionally, the patients with PTLD ranged from 11 to 17 years of age, which is older than previously reported cohorts of pediatric solid organ transplant recipients.
Further, several patients were discharged home three to 6 months after transplantation; "home" may be quite remote from the study center due to the regional nature of pediatric lung transplantation.
Thus, samples were not obtained during all symptomatic events if the patients were not evaluated at the study site during a symptomatic event, especially if the event was more than 3-6 months post-transplant. All PTLD events occurred at least 4 months posttransplant suggesting that early identification through WB or BAL screening could have been missed, especially in PTLD events further removed from the early post-transplant period. Nonetheless, this is the largest study in a pediatric lung transplant population to date and is the only prospective study performed that contains a cohort large enough to investigate the predictive power of EBV DNA levels for early recognition of PTLD. As the pediatric lung transplant centers that participated in this study followed a shared protocol for care, the opportunity for evaluation during symptomatic events was greatest within the first 3 months post-transplantation.
Furthermore, study centers followed standard immunosuppressive protocols and a difference in rejection episodes between the PTLD and non-PTLD patient populations was not detected.
In conclusion, further investigation is needed to identify screening methods for PTLD. Monitoring of the BAL fluid for EBV DNA was not useful in this study, and so other methods should be pursued. Possible avenues for investigation include refining immunosuppression protocols, increasing surveillance for signs and symptoms of PTLD, or identification of other biomarkers predictive of PTLD.
